Thomas John Bender1, Umid Sharapov2, Okey Utah3, Jian Xing2, Dale Hu2, Jolanta Rybczynska2, Jan Drobeniuc2, Saleem Kamili2, Philip R Spradling2, Anne C Moorman4. 1. Epidemic Intelligence Service Program, The Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control, Atlanta, GA, United States. 2. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, United States. 3. Virginia Department of Health, Richmond, VA, United States. 4. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: amoorman@cdc.gov.
Abstract
BACKGROUND: Failure to adhere to infection control guidelines, especially during assisted monitoring of blood glucose, has caused multiple hepatitis B outbreaks in assisted living facilities (ALFs). In conjunction with the response to such an outbreak at an ALF ("Facility X") where most residents had neuropsychiatric disorders, we evaluated seroprotection rates conferred by hepatitis B vaccine and assessed the influence of demographic factors on vaccine response. METHODS: Residents were screened for hepatitis B and C infection, and those susceptible were vaccinated against hepatitis A and hepatitis B with one dose of TWINRIX™ (GSK) given at 0, 1, and 7 months. Blood samples were collected 1-2 months after receipt of the third vaccine dose to test for antibody to hepatitis B surface antigen (anti-HBs). RESULTS: Of the 27 residents who had post-vaccination blood specimens collected, 22 (81%) achieved anti-HBs concentrations ≥10 mIU/mL. Neither age nor neuropsychiatric comorbidity was a significant determinant of seroprotection. Geometric mean concentration was lower among residents aged 60-74 years (74.3 mIU/mL) than among residents aged 46-59 years (105.3 mIU/mL) but highest among residents aged ≥75 years (122.5 mIU/mL). The effect of diabetes on vaccination response could not be examined because 16/17 (94%) diabetic residents had HBV infection by the time of investigation. CONCLUSIONS: Adult vaccine recipients of all ages, even those over 60 years of age, demonstrated a robust capacity for achieving hepatitis B seroprotection in response to the combined hepatitis A/hepatitis B vaccine. The role for vaccination in interrupting HBV transmission during an outbreak remains unclear, but concerns about age-related response to hepatitis B vaccine may be insufficient to justify foregoing vaccination of susceptible residents of ALFs. Published by Elsevier Ltd.
BACKGROUND: Failure to adhere to infection control guidelines, especially during assisted monitoring of blood glucose, has caused multiple hepatitis B outbreaks in assisted living facilities (ALFs). In conjunction with the response to such an outbreak at an ALF ("Facility X") where most residents had neuropsychiatric disorders, we evaluated seroprotection rates conferred by hepatitis B vaccine and assessed the influence of demographic factors on vaccine response. METHODS: Residents were screened for hepatitis B and C infection, and those susceptible were vaccinated against hepatitis A and hepatitis B with one dose of TWINRIX™ (GSK) given at 0, 1, and 7 months. Blood samples were collected 1-2 months after receipt of the third vaccine dose to test for antibody to hepatitis B surface antigen (anti-HBs). RESULTS: Of the 27 residents who had post-vaccination blood specimens collected, 22 (81%) achieved anti-HBs concentrations ≥10 mIU/mL. Neither age nor neuropsychiatric comorbidity was a significant determinant of seroprotection. Geometric mean concentration was lower among residents aged 60-74 years (74.3 mIU/mL) than among residents aged 46-59 years (105.3 mIU/mL) but highest among residents aged ≥75 years (122.5 mIU/mL). The effect of diabetes on vaccination response could not be examined because 16/17 (94%) diabetic residents had HBV infection by the time of investigation. CONCLUSIONS: Adult vaccine recipients of all ages, even those over 60 years of age, demonstrated a robust capacity for achieving hepatitis B seroprotection in response to the combined hepatitis A/hepatitis B vaccine. The role for vaccination in interrupting HBV transmission during an outbreak remains unclear, but concerns about age-related response to hepatitis B vaccine may be insufficient to justify foregoing vaccination of susceptible residents of ALFs. Published by Elsevier Ltd.
Authors: Matthew E Wise; Patricia Marquez; Umid Sharapov; Susan Hathaway; Kenneth Katz; Scott Tolan; Alina Beaton; Jan Drobeniuc; Yury Khudyakov; Dale J Hu; Joseph Perz; Nicola D Thompson; Elizabeth Bancroft Journal: Am J Infect Control Date: 2011-08-11 Impact factor: 2.918
Authors: William F Pirl; Joseph A Greer; Cynthia Weissgarber; Gabrielle Liverant; Steven A Safren Journal: Psychiatr Serv Date: 2005-12 Impact factor: 3.084
Authors: Roxanne E Williams; Arlene C Sena; Anne C Moorman; Zack S Moore; Umid M Sharapov; Jan Drobenuic; Dale J Hu; Hattie W Wood; Jian Xing; Philip R Spradling Journal: Vaccine Date: 2012-03-13 Impact factor: 3.641
Authors: P Rendi-Wagner; M Kundi; H Stemberger; G Wiedermann; H Holzmann; M Hofer; K Wiesinger; H Kollaritsch Journal: Vaccine Date: 2001-02-28 Impact factor: 3.641
Authors: Stanley D Rosenberg; Jeffrey W Swanson; George L Wolford; Fred C Osher; Marvin S Swartz; Susan M Essock; Marian I Butterfield; Bryan J Marsh Journal: Psychiatr Serv Date: 2003-06 Impact factor: 3.084
Authors: Mary F Brunette; Robert E Drake; Bryan J Marsh; William C Torrey; Stanley D Rosenberg Journal: Psychiatr Serv Date: 2003-06 Impact factor: 3.084
Authors: Dharmendra Kumar; Sharad Srivastava; M S Tevatia; Kanwaljit Kaur; Amit Sood; Manish Manrai; Reema Mukerjee Journal: Med J Armed Forces India Date: 2020-11-06